Outlining ZW1528, a Bispecific Antibody Targeting IL-4Ra & IL-33, Potently Inhibits Key Mediators of Airway Inflammation
- Discuss how ZW1528 high-affinity binding to IL-4Ra and IL-33 mediates potent blockade of IL-4, IL-13, and IL-33 pathways, and drives in vitro inhibition of type 2 and non-type 2 responses in primary immune cells of COPD patients
- Demonstrate that ZW1528 significantly reduces both systemic and local lung inflammation in mice with humanized IL-4/IL-4Ra
- Review ZW152’s good tolerability and favorable pharmacokinetics in the NHP and biomarkers of target blockade
- Unveil how these findings validate the rational design of ZW1528 and support its therapeutic potential across a range of airway inflammatory conditions